Sinclair Dunlop - Jan 1, 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Director
Signature: /s/ David Watson, attorney-in-fact for Sinclair Dunlop
Stock symbol: APLS
Transactions as of: Jan 1, 2022
Transactions value $: $0
Form type: 4
Date filed: 1/4/2022, 03:38 PM
Previous filing: Sep 13, 2021
Next filing: Apr 25, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Award	$0	+4.23K	+6.32%	$0.00	71.1K	Jan 1, 2022	Direct	F1
holding	APLS	Common Stock						301K	Jan 1, 2022	Epidarex	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Award	$0	+8.55K		$0.00	8.55K	Jan 1, 2022	Common Stock	8.55K	$47.28	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This represents a restricted stock unit grant made on 1/1/2022 that fully vest on the first anniversary of the date of grant, subject to continued service as a director.
F2	The securities are held by Epidarex and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein.
F3	This represents a non-qualified stock option grant made on 1/1/2022 that vests quarterly over 1 year from the date of grant, subject to continued service as a director, and expires seven years from the date of grant.